{"product_id":"ensidnib-enasidenib","title":"Ensidnib (Enasidenib)","description":"\u003ch2\u003eAbout Enasidenib\u003c\/h2\u003e\u003cp\u003eEnasidenib is a medication used to treat relapsed or refractory acute myeloid leukemia (AML) in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test.\u003csup id=\"cite_ref-Kim2017_2-0\" class=\"reference\"\u003e\u003c\/sup\u003e It is an inhibitor of IDH2. \u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Acute_Myeloid_Leukemia\"\u003eAcute Myeloid Leukemia\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for relapsed\/refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation \u003c\/p\u003e\u003cp\u003e100 mg PO qDay until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eIn patients without disease progression or unacceptable toxicity, treat for ≥6 months to allow time for clinical response\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Differentiation_syndrome\"\u003eDifferentiation syndrome\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf differentiation syndrome suspected, administer systemic corticosteroids; initiate hemodynamic monitoring\u003c\/li\u003e\n\u003cli\u003eInterrupt therapy if pulmonary symptoms (eg, intubation\/ventilator support) and\/or renal dysfunction persists for \u0026gt;48 hr post corticosteroid initiation\u003c\/li\u003e\n\u003cli\u003eResume once signs\/symptoms improve to Grade ≤2 (mild-moderate)\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Noninfectious_leukocytosis_WBC_30000_mcL\"\u003eNoninfectious leukocytosis (WBC \u0026gt;30,000 mcL)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eInitiate hydroxyurea, as per standard institutional guidelines\u003c\/li\u003e\n\u003cli\u003eInterrupt therapy if no improvement of leukocytosis after initiating hydroxyurea\u003c\/li\u003e\n\u003cli\u003eResume at 100 mg\/day when WBC \u0026lt;30,000 mcL\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Bilirubin_elevated_3x_ULN\"\u003eBilirubin elevated \u0026gt;3x ULN\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf sustained for ≥2 weeks without elevated AST\/ALT or other hepatic disorders, reduce dose to 50 mg\/day\u003c\/li\u003e\n\u003cli\u003eResume at 100 mg\/day if bilirubin elevation resolves to ≤2x ULN\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_Grade_3_toxicities_eg_tumor_lysis_syndrome\"\u003eOther Grade ≥3 toxicities (eg, tumor lysis syndrome)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eInterrupt therapy until toxicity resolve Grade ≤2\u003c\/li\u003e\n\u003cli\u003eIf toxicities resolve (Grade ≤1), resume at 50 mg\/day; may increase to 100 mg\/day\u003c\/li\u003e\n\u003cli\u003eIf Grade≥3 recurs, discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Monitoring_parameters\"\u003eMonitoring parameters\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAssess baseline blood cell counts and chemistries for leukocytosis and tumor lysis syndrome before initiation; monitor at least q2week for at least first 3 months of treatment\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients for treatment based on presence of IDH2 mutations in the blood and bone marrow\u003c\/li\u003e\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797956358187,"sku":"RL202501s220s290","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-2391.png?v=1787022259","url":"https:\/\/xomeds.com\/products\/ensidnib-enasidenib","provider":"XOMEDS","version":"1.0","type":"link"}